Introduction {#s1}
============

Seven randomized-controlled studies have consistently shown that patients with a large vessel occlusion (LVO) in the anterior circulation benefit from mechanical thrombectomy (MTE) following intravenous thrombolysis (IVT) with tPA.[@R1] Currently it is unclear if IVT before MTE adds additional benefit[@R8] and this question will be assessed in two randomized-controlled studies (SWIFT DIRECT, MR CLEAN NO IV). The individual patient data meta-analysis of the pivotal thrombectomy trials found no interaction between the treatment effect size of MTE and IVT pretreatment status[@R12] and a recently published study-level meta-analysis found no significant difference in outcome between patients with and without pretreatment with IVT.[@R13] In contrast, another meta-analysis has suggested that IVT+MTE patients had better functional outcomes, lower mortality, higher rates of successful recanalization, and equal odds of symptomatic intracerebral hemorrhage compared with patients treated with direct MT (dMTE).[@R14] However, the aforementioned analyses may in part be confounded by the eligibility for IVT, potentially leading to group imbalances in stroke etiology, risk factors, and time to treatment.

To account for such group imbalances more systematically, the present meta-analysis on a comparison of IVT+MTE versus dMTE will distinguish between studies including dMTE patients eligible for IVT (IVT-E) and studies including dMTE patients ineligible for IVT (IVT-IN), as the latter may be a major source of selection bias. In addition, baseline risk factor distribution in both groups will be evaluated to quantify selection bias.

Methods {#s2}
=======

This study-level meta-analysis was presented in a manner adherent to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.[@R15] The checklist outlined by the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) consortium was also applied. The authors declare that all supporting data are available within the article and its online [supplementary files](#SP1){ref-type="supplementary-material"}. Extracted raw data can be found in the online [supplementary dataset 1](#SP2){ref-type="supplementary-material"}.
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Search strategy and selection criteria {#s2a}
--------------------------------------

Information about the search strategy and accessed databases can be found as additional information in the Online Supplement ([supplementary additional information 1 and table I-IV](#SP1){ref-type="supplementary-material"}).

All identified studies were imported into EndNote (version X, Clarivate Analytics, Phiadelphia, USA) and an automatic deduplication was performed. After the deduplication procedure, studies were reviewed for eligibility concerning the quantitative analysis by two independent raters (JK, PM) and by a third rater in cases of discrepancies (UF). Prespecified inclusion criteria can be found in the Online Supplement ([supplementary additional information 2](#SP1){ref-type="supplementary-material"}).

Studies were categorized as comparing dMTE in IVT-eligible patients (=IVT-E) with IVT+MTE in IVT-eligible patients or comparing dMTE in IVT-ineligible patients (=IVT-IN) with IVT+MTE in IVT-eligible patients. Studies reporting on both IVT-E and IVT-IN patients were included if separate analyses of these groups had been presented in the published full text article, or if the relevant data discriminating between the two groups were made available after contacting the respective corresponding authors. If a study provided comparison of a matched and unmatched control group, the matched-pair analysis was used for further calculation in order to reduce the risk of bias. Any matched-pair analysis was excluded from the analyses regarding risk-factor distribution between dMTE and IVT+MTE patients.

Extraction of baseline and outcome data {#s2b}
---------------------------------------

Data were extracted by JK according to a standardized extraction sheet and cross-checked by a second reader. A full list with the study data and outcomes extracted, as well as contact processes with the authors can be found as additional information in the Online Supplement ([supplementary additional information 3](#SP1){ref-type="supplementary-material"}).

Statistical analysis and quality assessment {#s2c}
-------------------------------------------

Pooled effect sizes were calculated using the inverse variance heterogeneity (IVhet) model, assuming heterogeneous studies and the presence of multiple true effect sizes.[@R16] The assumption was based on the heterogeneous inclusion and exclusion criteria of the respective studies. The IVhet model is considered as an improved alternative to the random effect model which uses an estimator under the fixed effect model assumption with a quasi-likelihood based variance structure.[@R16] For all outcomes included in the analysis, we calculated the corresponding summary ORs and respective 95% CIs to express the comparison of dMTE vs IVT+MTE.

Pooled effect sizes were further calculated and stratified according to IVT-E and IVT-IN studies. Other subgroup analyses were performed according to the study type (ie, confined analysis to RCT subgroup analyses). For further information regarding influence analysis, assessment of heterogeneity and evaluation of publication bias, see Online Supplement ([supplementary additional information 4](#SP1){ref-type="supplementary-material"}). Quality assessment was performed as denoted in the Online Supplement ([supplementary additional information 5](#SP1){ref-type="supplementary-material"}). Data were analyzed and displayed using the software package MetaXL (EpiGear International, Sunrise Beach, Queensland, Australia) for Microsoft Excel.

Results {#s3}
=======

Literature search {#s3a}
-----------------

The search strategies yielded 2747 unique publications, among which 2617 were excluded on abstract and title screening. After retrieving the full texts of the remaining 130 studies, 20 met all study selection criteria and were included into quantitative synthesis (see online [supplementary figure 1](#SP1){ref-type="supplementary-material"} for literature search flow diagram, [table 1](#T1){ref-type="table"} for study characteristics).[@R1] Reporting rates of the primary and secondary outcomes are denoted in online [supplementary table V](#SP1){ref-type="supplementary-material"}. Further information regarding the results of the literature search is provided in the Online Supplement ([supplementary additional information 6](#SP1){ref-type="supplementary-material"}).

###### 

Study characteristics of included analyses

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                               Study type   MC              Registry/RCT name         IVT-E/IVT-IN   Matching                              n             Age        Admission NIHSS   STG (min)   D/ITG (min)   TICI               Grading sICH       POI                                                                                                                                                
  ----------------------------------- ------------ --------------- ------------------------- -------------- ------------------------------------- ------------- ---------- ----------------- ----------- ------------- ------------------ ------------------ --------- -------------- ------------ ------------- ------------- ------------ ------------- ------ ---------------------------------------------- ------
  Broeg-Morvay *et al* [@R17]         PO           --              Bernese Stroke Registry   IVT-E          √                                     40            40         77+/−14           78+/−12     0.85          17 range (4--38)   17 range (4--36)   0.85      229+/−79       262+/−85     **0.01²**     N/A           N/A          N/A           m      PROACT II                                      −

  Wang *et al* [@R18]                 PO           √               ACTUAL                    IVT-E          √                                     138           138        67\               67\         0.58          16\                17\                0.50      N/A            N/A          N/A           106\          147\         **\<0.001**   m      HBC                                            −
                                                                                                                                                                           (59--75)          (59--73)                  (13--21)           (13--21)                                                               (61--135)     (114--200)                                                                       

  Weber *et al* [@R19]                RO           −               N/A                       IVT-E/IN       −                                     145\          105        69+/−15           70+/−13     0.882         15\                16\                0.215     210\           233\         0.103         112\          148\         **\<0.001**   m      ECASS III                                      √³
                                                                                                                                                  (70 IVT-E,\                                                          (9--19)            (12--20)                     (152--330)     (198--295)                 (60--153)     (122--167)                                                                       
                                                                                                                                                  75 IVT-IN)                                                                                                                                                                                                                                                    

  Sanak *et al* [@R31]                RO           √               N/A                       IVT-IN         −                                     179           193        66+/−12           63+/−14     N/A           15                 18                 \<0.001   N/A            N/A          N/A           N/A           N/A          N/A           n.s.   SITS-MOST                                      −

  Coutinho *et al* [@R20]             RCT/\        √               SWIFT/STAR                IVT-IN         −                                     131           160        69+/−12           67+/−13     0.14          17\                17\                0.86      262\           254\         0.10          79\           79\          0.46          M      ICH w NIHSS increase≥4 or death                −
                                      PO[@R1]                                                                                                                                                                          (13--20)           (13--20)                     (201--375)     (195--305)                 (54--120)     (49--111)                                                                        

  Abilleira *et al* [@R21]            PO           √               SONIA                     IVT-IN         −                                     599           567        68+/−14           69+/−13     0.464         17\                17\                0.627     300\           246\         **\<0.001**   N/A           N/A          N/A           M      SITS-MOST                                      −
                                                                                                                                                                                                                       (12--20)           (13--20)                     (174.564)      (186--318)                                                                                                                

  Kaesmacher *et al* [@R32]           RO           −               N/A                       IVT-IN         −                                     79            160        73+/−12           70+/−16     0.083         15\                15\                0.851     195\           195\         0.913         N/A           N/A          N/A           O      N/A                                            −
                                                                                                                                                                                                                       (11--18)           (11--17)                     (135--256)     (157--247)                                                                                                                

  Behme *et al* [@R33]                RO           √               N/A                       IVT-IN         −                                     27            66         74\               74\         0.30          17+/−8             16+/−6             0.70      192\           194\         0.50          N/A           N/A          N/A           M      N/A                                            −
                                                                                                                                                                           (48--91)          (32--91)                                                                  (72--329)      (83--396)                                                                                                                 

  Guedin *et al* [@R22]               RO           −               N/A                       IVT-IN         −                                     40            28         65+/−15           69+/−14     0.24          15\                18\                0.39      204\           240\         0.62          N/A           N/A          N/A           n.s.   PH2 with NIHSS increase≥4                      −
                                                                                                                                                                                                                       (10--20)           (13--19)                     (175--290)     (187--275)                                                                                                                

  Maier *et al* [@R23]                RO           −               N/A                       IVT-IN         −                                     28            81         76\               75\         0.827         13\                17\                0.013     174\           153\         0.365         N/A           N/A          N/A           M      ICH within 48 h w NIHSS increase of≥4 points   −
                                                                                                                                                                           (63--80)          (62--80)                  (8--18)            (11--21)                     (120--253)     (120--213)                                                                                                                

  Rai *et al* [@R24]                  RO           −               N/A                       IVT-IN         −                                     52            38         69+/−18           63+/−19     0.15          16\                18\                0.08      319+/−270      106+/−52     **\<0.001**   47+/−32       60+/−33      0.054         m      N/A                                            −
                                                                                                                                                                                                                       (10--22)           (13--23)                                                                                                                                                              

  Leker *et al* [@R25]                RO           −               N/A                       IVT-IN         −                                     33            24         64+/−15           67+/−14     0.53          N/A                N/A                N/A       284+/−132      242+/−71     0.17          140+/−97      149+/−63     0.73          O      N/A                                            −

  Minnerup *et al* [@R26]             PO           √               REVASK                    IVT-IN         −                                     504           603        69+/−15           68+/−14     N/A           15 (9)             15 (7)             N/A       294+/−227      233+/−179    **\<0.001**   N/A           N/A          N/A           N/A    N/A                                            √^4^

  Alonso de Lecinana *et al* [@R27]   PO           √               FUN-TPA                   IVT-IN         −                                     21            53         74\               64\         **0.006**     19\                17\                0.24      210\           275\         **0.02**      N/A           N/A          N/A           O      SITS-MOST                                      √^5^
                                                                                                                                                                           (66--78)          (51--73)                  (13--22)           (14--22)                     (168--257)     (225--345)                                                                                                                

  Davalos *et al* [@R28]              RO           √               N/A                       IVT-IN         −                                     67            74         66+/−14           66+/−13     N/A           18\                17\                          330\           290\         N/A           N/A           N/A          N/A           M      PH2                                            √^6^
                                                                                                                                                                                                                       (15--29)           (11--21)                     (195--605)     (225--360)                                                                                                                

  Nogueira *et al* [@R51]             PO           √               NASA                      IVT-IN         −                                     179           136        68+/−14           67+/−16     0.8           18+/−6             19+/−7             0.3       N/A            N/A          N/A           N/A           N/A          N/A           M      N/A                                            √^7^

  Wee *et al* [@R61]                  RO           −               N/A                       IVT-IN         −                                     29            21         71+/−14           73+/−16     0.745         15+/−7             15+/−7             0.780     220+/−187      165+/−60     0.204         N/A           N/A          N/A           M      ECASS II                                       −

  Mulder *et al* [@R30]               RCT          √               MR CLEAN                  IVT-IN         −                                     30            203        65\               68\         N/A           19\                18\                N/A       242\           265\         N/A           N/A           N/A          N/A           O                                                     −
                                                                                                                                                                           (54--76)          (62--78)                  (14--22)           (14--22)                     (200--300)     (214--315)                                                                                                                

  Goyal *et al* [@R5]                 RCT          √               ESCAPE                    IVT-IN         −                                     45            120        71+/−16           70+/−12     N/A           15.5\              17\                N/A       359\           162\         **\<0.01**    48\           53\          N/A           M      ECASS II                                       −
                                                                                                                                                                                                                       (12--21)           (13--20)                     (193.5--551)   (140--236)                 (28--65)      (40--74)                                                                         

  Jovin *et al* [@R1]                 RCT          √               REVASCAT                  IVT-IN                                               33            70         66+/−11           66+/−12     N/A           18+/−4             16+/−5             N/A       281+/−114      267+/−83.7   N/A           74.3+/−27.6   64+/−28.3    N/A           M      SITS-MOST                                      −

  Summary                             4 RCT,\      12 MC studies                             2 IVT-E\       two studies performed case matching   **2399**      **2880**                                                                                                                                                                                                                                        5
                                      6 PO,\                                                 1 IVT-E/IN\                                                                                                                                                                                                                                                                                                        
                                      10 RO                                                  17 IVT-IN                                                                                                                                                                                                                                                                                                          
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

1, combined data of SWIFT and STAR; 2, unmatched cohorts; 3, 20.4%; 4, 12.0%; 5, 7.6%; 6, 13.5%; 7, 10.8%; MC, multi-center; RO, retrospective observational; PO, prospective observational; PH-RCT, post-hoc randomized controlled trial analysis; RCT, randomized controlled trial; IVT-E, direct mechanical thrombectomy patients eligible for IVT; IVT-IN, direct mechanical thrombectomy patients ineligible for IVT; dMTE, direct mechanical thrombectomy; IVT+MTE, intravenous thrombolysis and mechanical thrombectomy; STG, symptom onset to groin puncture interval; D/ITG, door or imaging to groin puncture interval; TICI, thrombolysis in cerebral Infarction; m, modified; o, original; n.s., not specified; sICH, symptomatic intracranial hemorrhage; POI, posterior occlusions included; N/A, not available; PROACT, intra-arterial prourokinase for acute ischemic stroke; ECASS, European Cooperative Acute Stroke Study; SITS-MOST, safe implementation of thrombolysis in stroke-monitoring study in Italy; w, with; PH2, parenchymal hematoma type 2 according to the ECASS I criteria; data are generally displayed as mean +/-SD deviation or median (IQR) if not otherwise specified.

Baseline characteristics and risk factor distribution {#s3b}
-----------------------------------------------------

For detailed information see [Supplementary additional](#SP1){ref-type="supplementary-material"} information 7. In short, IVT-IN dMTE patients were treated later and had more comorbidities including higher odds for a medical history of atrial fibrillation (sOR 1.94, 95% CI 1.50 to 2.50, online [supplementary figure IV](#SP1){ref-type="supplementary-material"}) and prior cerebrovascular events (sOR 1.94, 95% CI 1.60 to 2.35, online [supplementary figure IV](#SP1){ref-type="supplementary-material"}).

Functional independence at day 90 {#s3c}
---------------------------------

Rates of functional independence at 3 months were reported in 17 studies (2 IVT-E, 1 IVT-E, and IVT-IN, 14 IVT-IN, 4657 patients). Overall, there was a non-significant trend that patients undergoing dMTE have lower rates of functional independence at day 90 as compared with IVT+MTE patients (sOR 0.82, 95% CI: 0.65 to 1.03, [figure 1](#F1){ref-type="fig"}). However, heterogeneity was substantial (I²: 51%, Q=35.01, P=0.01). Influence analysis provided evidence that the exclusion of three single studies (Weber et al,[@R19] Abilleira et al,[@R21] and Sanak et al[@R31]) would result in a significant association between dMTE and lower rates of good functional outcome (data not shown). Analysis confined to RCTs, comparing dMTE in IVT-IN patients and IVT+MTE in IVT-E patients, showed no differences between the groups, as evidenced by a point estimation of sOR 0.80 (95% CI 0.58 to 1.12, online [supplementary figure VII](#SP1){ref-type="supplementary-material"}).
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Among just the studies comparing dMTE in IVT-E patients with IVT+MTE in IVT-E patients, rates of functional independence at 3 months did not differ between the treatment groups (sOR 1.08, 95% CI 0.67 to 1.76, [figure 1](#F1){ref-type="fig"}).

Mortality at day 90 {#s3d}
-------------------

Rates of mortality at day 90 were reported in 18 studies (2 IVT-E, 1 IVT-E/IN, and 15 IVT-IN studies, 4929 patients). Patients undergoing dMTE had higher odds for a fatal outcome at day 90 (sOR 1.35, 95% CI 1.07 to 1.71, [figure 2](#F2){ref-type="fig"}). No substantial heterogeneity was noted, with 39%, 27.70, and P=0.05 for I^2^, Q, and corresponding p, respectively. Influence analysis provided evidence that the exclusion of one study (Minnerup et al[@R26]) resulted in loss of significance (data not shown). Restriction to RCT data, comparing dMTE in IVT-IN patients and IVT+MTE in IVT-E patients, provided a comparable point estimate as other IVT-IN studies (sOR 1.83, 95% CI 1.16 to 2.91, online [supplementary figure VIII](#SP1){ref-type="supplementary-material"}).
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In the analysis confined to studies comparing dMTE in IVT-E patients with IVT+MTE in IVT-E patients, no effect of treatment group on mortality was noted (sOR 0.84, 95% CI 0.40 to 1.75, [figure 2](#F2){ref-type="fig"}).

Successful reperfusion {#s3e}
----------------------

Nineteen studies reported on rates of successful reperfusion of IVT+MTE versus dMTE (2 IVT-E, 1 IVT-E, and IVT-IN, 16 IVT-IN, 4220 patients). Overall, there was no evidence that rates of successful reperfusion differed in dMTE and IVT+MTE patients (sOR 0.93, 95% CI 0.68 to 1.28, [figure 3](#F3){ref-type="fig"}). I² and Cochrances Q statistics were I²=51% (95% CI: 19% to 71%) and Q=39.02, P\<0.01, indicating substantial heterogeneity. Influence analysis did not provide evidence that the sOR changed significantly when excluding single studies (data not shown). Similar rates of successful reperfusion were also observed when the analysis was confined to analyses of RCTs with dMTE in IVT-IN patients and IVT+MTE in IVT-E patients (sOR 1.32, 95% CI 0.89 to 1.95, online [supplementary figure IX](#SP1){ref-type="supplementary-material"}). Among nine studies (1753 patients) reporting rates of complete (TICI3) reperfusion, no difference between dMTE and IVT+MTE patients was noted (sOR 0.98, 95% CI 0.80 to 1.21, see online [supplementary figure X](#SP1){ref-type="supplementary-material"}).

![Summary OR of dMTE patients for successful reperfusion. \*matched-pair analysis; IVT-E, IVT-eligible dMTE patients; IVT-IN, IVT-ineligible dMTE patients.](neurintsurg-2018-013834f03){#F3}

When assessing the rates of successful reperfusion only for studies comparing dMTE in IVT-E patients with IVT+MTE in IVT-E patients (n=531 patients), there was a non-significant trend for higher rates of successful reperfusion in the dMTE group (sOR 1.67, 95% CI 0.95 to 2.94, [figure 3](#F3){ref-type="fig"}).

Symptomatic intracerebral hemorrhage {#s3f}
------------------------------------

Rates of sICH were reported in 16 studies (3903 patients, see [table 1](#T1){ref-type="table"} for respective definition of sICH in the different studies). IVT+MTE patients nominally had more sICH (sOR 0.86, 95% CI 0.63 to 1.17, [figure 4](#F4){ref-type="fig"}) without reaching statistical significance.
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Considering only the studies comparing dMTE in IVT-E patients with IVT+MTE in IVT-E patients, no treatment group effect on sICH rates was noted (sOR 0.95, 95% CI 0.51 to 1.76, [figure 4](#F4){ref-type="fig"}).

Asymptomatic intracerebral hemorrhage {#s3g}
-------------------------------------

The reporting frequency for aICH was 75% (15/20 studies, 3635 patients). Two IVT-E, 12 IVT-IN studies and one IVT-E/IN study had analyzable data. The odds for aICH did not differ between dMTE and IVT+MTE patients (sOR 0.93, 95% CI 0.72 to 1.19, online [supplementary figure XI](#SP1){ref-type="supplementary-material"}). The observed heterogeneity was low overall.

However, in the analysis restricted to studies comparing dMTE in IVT-E patients with IVT+MTE in IVT-E patients, dMTE was associated with lower rates of aICH (sOR 0.49, 95% CI 0.30 to 0.81, online [supplementary figure XI](#SP1){ref-type="supplementary-material"}).

Quality and bias assessment {#s3h}
---------------------------

Risk of bias was noted in all studies, with the most common source being nonrandom allocation to treatment groups, present in all. Studies differed in sources of potential bias most often with regard to: blinding of outcome assessment; comparability of baseline characteristics between treatment groups; and non-reporting of whether some patients not undergoing MTE after IVT did so because of preinterventional reperfusion or because of neurological improvement or other reasons (intention to treat reporting, see online [supplementary table VII](#SP1){ref-type="supplementary-material"}). A minor to moderate funnel and doi plot asymmetry was present for most of the analyses performed (see online [supplementary figure XII](#SP1){ref-type="supplementary-material"}).

Discussion {#s4}
==========

A substantial body of observational and indirect RCT comparison investigations analyzing direct mechanical thrombectomy alone vs combined intravenous tPA plus mechanical thrombectomy has now been accumulated, comprising 20 studies and 5279 patients. Intriguingly, in the pooled analysis of three of the studies contrasting both treatment strategies in highly comparable patients -- those eligible for IV tPA -- direct mechanical thrombectomy alone showed equal rates of substantial reperfusion and lower rates of asymptomatic hemorrhagic transformation, though no differences in 3-month functional independence and mortality. Treatment strategy effects were less consistent when these data were combined with studies contrasting both treatment strategies in less comparable patients (patients with dMTE who were ineligible for IVT). In these patients, dMTE compared with IVT+MTE was associated with a tendency for less symptomatic hemorrhage but higher 3-month mortality.

Comparison with previous meta-analyses {#s4a}
--------------------------------------

The findings of the present systematic analysis are consonant by definition with prior component studies, as the meta-analysis encompasses all identified individual investigations. Our findings do however contrast with those of a recent meta-analysis.[@R14] That study reported lower reperfusion rates and inferior clinical outcomes among dMTE compared with IVT+MTE patients.[@R14] However, that analysis was confined to a smaller group of studies (13 instead of 20), and included only one of the three studies with comparable, IVT-eligible patients in both treatment arms. In contrast, another meta-analysis performed by Phan et al[@R13] showed equal rates of good functional outcome and 90-day mortality between dMTE and IVT+MTE patients. These discrepant results may partially be due to different inclusion criteria, as Phan et al[@R13] also included studies evaluating posterior circulation strokes and a few studies which included first-generation mechanical thrombectomy devices.[@R13] Another reason which may partially explain these discrepancies is the difference with regards to the inclusion of studies assessing dMTE in IVT-eligible patients.[@R13] The current, meta-analysis suggests that, among IVT-eligible patients, dMTE is associated with equal rates of good angiographic results and may protect from asymptomatic hemorrhagic transformation. Hence, some reassurance is provided that reperfusion rates are unlikely to be substantially lower for dMTE patients. The results suggests caution in reaching conclusions from comparisons of dMTE in IVT-ineligible patients with IVT+MTE in IVT-eligible patients. The features that cause patients to be IVT-ineligible also often predispose to lesser technical and clinical success. Those factors may include greater time since onset (allowing more thrombus impaction), recent surgery (greater co-morbidities), and anticoagulation therapy at onset (increased hemorrhagic risk). The current analysis fails to provide evidence for clear benefits of one treatment approach over the other but rather points toward clinical equipoise regarding the best treatment strategy and wariness regarding comparison of unlike patients, indicating a need for formal testing in randomized-controlled trials.

Reperfusion {#s4b}
-----------

Numerous theoretical considerations have been proposed supporting both potentiation of MTE reperfusion by preceding IVT (eg, thrombus softening and lysis of downstream emboli),[@R35] and reduction of MTE reperfusion by preceding IVT (eg, thrombus fragmentation and procedure delay with further clot organization).[@R36] We analyzed rates of complete (TICI 3) as well as successful (TICI 2B/3) reperfusion, as multiple studies have suggested that complete reperfusion is associated with better clinical outcomes than moderately successful reperfusion.[@R37] As it is conceivable that IV fibrinolysis might distinctively clear small distal thrombi,[@R35] enabling complete rather than moderately successful reperfusion, this topic is of interest. However, in concordance with the findings regarding successful reperfusion, no difference was noted in rates of complete reperfusion (TICI3) between dMTE and IVT+MTE strategies.

Functional outcome {#s4c}
------------------

Important confounding factors were observed in the analysis comparing dMTE in IVT-ineligible patients with IVT+MTE in IVT-eligible patients. The IVT-ineligible patients had worse baseline profiles, including more frequent history of atrial fibrillation, more frequent history of prior cerebrovascular events, and longer total ischemia time prior to start of the thrombectomy procedure. Patients with ischemic stroke and history of atrial fibrillation (AF), compared with non-AF patients, have larger cerebral infarcts, more severe presenting deficits, more frequent post-stroke medical and neurological complications, and worse long-term clinical outcomes.[@R43] Especially when favorable outcome is evaluated with the modified Rankin Scale, stroke outcomes have been shown to be dependent on preexisting comorbidities such as prior strokes.[@R46] Finally, longer time to treatment start is a substantial risk factor for worsened clinical outcome.[@R47] Importantly, no difference in rates of good functional outcome were noted when analyses was limited to dMTE patients who were IVT-eligible. This observation was also shared in a patient-level pooled analyses of the data from two articles included in the IVT-eligible subgroup.[@R11]

Hemorrhagic complications {#s4d}
-------------------------

Hemorrhagic transformation is a feared complication of cerebral ischemia associated with high morbidity and mortality.[@R48] In patients treated with MTE, occurrence of intracranial hemorrhage is favored by delayed treatment, a proximal occlusion site, cardioembolic origin, poor collaterals, reperfusion success, and extended early ischemic damage.[@R49] In patients not treated with MTE, IV tPA facilitates the occurrence of intracranial hemorrhage as compared with placebo.[@R53] In the present meta-analysis, we found signals -- albeit weak -- that IV tPA added to MTE, compared with MTE alone, increases the likelihood of hemorrhagic transformations.

Limitations {#s5}
===========

This study has several important limitations. First, all studies included in the meta-analysis had potential sources of bias, limiting the strength of conclusions. Second, heterogeneity between studies was noted for some analyses. The use of a conservative statistical approach (inverse variance heterogeneity model)[@R24] and of sensitivity analyses dropping individual studies mitigated, but presumably could not entirely account for, heterogeneity effects. Third, we implemented the data of two studies, which performed case-matching in order to reduce the risk of bias owning to differences in baseline characteristics. However, case-matching may also increase the risk of hidden bias and may thus produce artificial results.[@R25] Fourth, we did not publish an analysis protocol ahead of the initiation of the meta-analysis. Last, the most important limitation arises due to the fact that several of the studies did not report on patients who were treated with a combined IVT+MTE strategy, but only received the IVT component as they reperfused or clinically improved with IVT alone, before MTE initiation. As a result, this potentially important advantage of the bridging approach was not fully incorporated in the present analysis and deserves future research. Although IVT clearly favors recanalization in patients with LVO,[@R55] reperfusion may not occur early enough and reported rates of reperfusions after IVT and prior to the start of MTE are low in patients with an intention to bridge (\~10%).[@R1] [@R60] Especially non-transfer patients with short needle to groin puncture intervals, a proximal occlusion, and a high thrombus burden are unlikely to respond to IVT.[@R58] Given these considerations, SWIFT DIRECT (<https://clinicaltrials.gov/ct2/show/NCT03192332>) will only include non-transfer patients with a proximal occlusion in whom endovascular treatment can be initiated rapidly.

Conclusion {#s6}
==========

The overall quality of evidence regarding the relative merits of IVT+MTE versus dMTE is low. In contrast to previous synopses and when analysis is confined to studies with a low risk of selection bias (ie, comparable IVT-eligible patients in both treatment strategy groups), the data suggest that for patients who finally undergo MTE, dMTE may offer comparable safety and efficacy as compared with IVT+MTE. Outcome comparisons yield mixed results when less comparable patients are considered (dMTE in IVT-ineligible patents vs IVT+MTE in IVT-eligible patients), but there is evidence of confounding by indication. The available data does provide substantial indications of clinical non-inferiority, suggesting that the conduct of randomized clinical trials evaluating dMTE versus IVT+MTE in LVO patients is appropriate when including only major vessel occlusions and when rapid access to endovascular treatment can be assured. The value of preinterventional recanalization in IVT+MTE needs further evaluation and should be reported more consistently.
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